First Bank & Trust Purchases New Holdings in Cytokinetics, Incorporated (NASDAQ:CYTK)

First Bank & Trust acquired a new position in shares of Cytokinetics, Incorporated (NASDAQ:CYTK) in the first quarter, according to its most recent disclosure with the SEC. The firm acquired 6,454 shares of the biopharmaceutical company’s stock, valued at approximately $452,000.

Several other hedge funds and other institutional investors also recently modified their holdings of CYTK. GAMMA Investing LLC purchased a new stake in shares of Cytokinetics during the 4th quarter worth about $80,000. Sage Rhino Capital LLC acquired a new stake in Cytokinetics in the fourth quarter worth $204,000. Caprock Group LLC acquired a new position in Cytokinetics during the 4th quarter valued at about $216,000. PNC Financial Services Group Inc. raised its stake in Cytokinetics by 4.8% during the 3rd quarter. PNC Financial Services Group Inc. now owns 7,373 shares of the biopharmaceutical company’s stock valued at $217,000 after acquiring an additional 340 shares in the last quarter. Finally, Journey Strategic Wealth LLC bought a new position in Cytokinetics in the 4th quarter valued at about $243,000.

Insider Activity at Cytokinetics

In other Cytokinetics news, EVP Fady Ibraham Malik sold 7,300 shares of the business’s stock in a transaction dated Tuesday, June 25th. The shares were sold at an average price of $53.72, for a total value of $392,156.00. Following the completion of the transaction, the executive vice president now directly owns 133,004 shares of the company’s stock, valued at $7,144,974.88. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. In related news, CAO Robert Wong sold 13,011 shares of Cytokinetics stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $48.88, for a total value of $635,977.68. Following the completion of the sale, the chief accounting officer now directly owns 16,653 shares in the company, valued at $813,998.64. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Fady Ibraham Malik sold 7,300 shares of the company’s stock in a transaction dated Tuesday, June 25th. The shares were sold at an average price of $53.72, for a total transaction of $392,156.00. Following the transaction, the executive vice president now owns 133,004 shares in the company, valued at $7,144,974.88. The disclosure for this sale can be found here. Insiders sold 140,393 shares of company stock valued at $8,284,390 over the last ninety days. 3.40% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the stock. Barclays reduced their price objective on shares of Cytokinetics from $100.00 to $95.00 and set an “overweight” rating for the company in a research report on Thursday, May 23rd. Raymond James decreased their price target on shares of Cytokinetics from $92.00 to $70.00 and set an “outperform” rating on the stock in a research report on Thursday, May 23rd. Oppenheimer reduced their price objective on Cytokinetics from $107.00 to $106.00 and set an “outperform” rating for the company in a research note on Thursday, May 9th. B. Riley cut their target price on Cytokinetics from $122.00 to $92.00 and set a “buy” rating on the stock in a research report on Tuesday, June 4th. Finally, JMP Securities decreased their price target on Cytokinetics from $106.00 to $78.00 and set a “market outperform” rating for the company in a research report on Tuesday, May 28th. One analyst has rated the stock with a sell rating, three have issued a hold rating and fifteen have given a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $77.06.

Cytokinetics Trading Up 0.7 %

Shares of NASDAQ:CYTK opened at $54.18 on Friday. The business’s fifty day moving average price is $56.77 and its two-hundred day moving average price is $67.03. Cytokinetics, Incorporated has a fifty-two week low of $25.98 and a fifty-two week high of $110.25.

Cytokinetics (NASDAQ:CYTK) last released its quarterly earnings results on Wednesday, May 8th. The biopharmaceutical company reported ($1.33) EPS for the quarter, missing analysts’ consensus estimates of ($1.16) by ($0.17). The business had revenue of $0.84 million for the quarter, compared to analysts’ expectations of $0.91 million. During the same quarter in the previous year, the business posted ($1.38) EPS. The firm’s quarterly revenue was down 81.8% on a year-over-year basis. Sell-side analysts predict that Cytokinetics, Incorporated will post -4.5 EPS for the current year.

Cytokinetics Profile

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.